New vaccine hope in fight against pneumonia and meningtis

New vaccine hope in fight against pneumonia and meningtis
 
Dramatic advance in understanding of how the body fights bacteria paves way for more effective vaccines

 
Issued jointly by University of Leicester and Trinity College Dublin on 12 November 2010

Image available from [email protected] : A dendritic cell infected with Streptococcus pneumoniae (Courtesy of  Edel McNeela and Jim Harris)

A new breakthrough in the fight against pneumonia, meningitis and septicaemia has been announced today by scientists in Leicester and Dublin.

The discovery will lead to a dramatic shift in our understanding of how the body's immune system responds to infection caused by Streptococcus pneumoniae and pave the way for more effective vaccines.

The collaborative research, jointly led by Dr Aras Kadioglu from the University of Leicester and Dr Ed Lavelle from Trinity College Dublin, with Dr Edel McNeela of TCD as its lead author, has been published in the  international peer-reviewed journal PLoS Pathogens.

The research was carried out by the teams from Leicester and Dublin with collaborators from the U.S and Switzerland over four years and supported by Science Foundation Ireland, Enterprise Ireland, the Medical Research Council (MRC) and the Meningitis Research Foundation.

The two teams say they have shown for the first time that the bacterial toxin pneumolysin triggers an immune response by activating a recently discovered group of proteins, called the NLRP3 inflammasome. Once activated, the inflammasome provides protection against infection caused by this pathogen.

The Leicester and Dublin research groups demonstrated that this mechanism operates independently of other previously described immune response proteins - contrary to a dogma in the field.

Importantly, this paper is the first to demonstrate that the NLRP3 inflammasome is essential to the immune response against infection by the pathogen and that the bacterial toxin pneumolysin is the key driver of this process.  The researchers state that this new knowledge of how the toxin interacts with the immune system will mean that new vaccines can be developed and targeted more effectively.

Describing the results as exciting, the researchers say it will potentially have a significant impact on vaccine development against pneumococcal disease.

Dr. Aras Kadioglu, Reader in Respiratory Infection in the Department of Infection, Immunity & Inflammation at the University of Leicester said: "This is a major breakthrough in our understanding of the immune response to Streptococcus pneumoniae; a human pathogen of global significance, responsible for over one million infant deaths annually and the major cause of illness and death in the elderly from infections of the respiratory tract. In order to develop improved pneumococcal vaccines for both the very young and the elderly, it is essential to understand how this bacterium interacts with the host immune system. The discoveries described in our paper represent a huge stride towards this objective. That is why these are exciting new findings, discovered in the course of a unique collaboration between scientists at the University of Leicester and Trinity College Dublin."

Dr Lavelle, who is Lecturer in Immunology in the School of Biochemistry and Immunology, Trinity College Dublin, said: "This is a very exciting finding and supports the development of inflammasome activating vaccines to prevent pneumococcal diseases including pneumonia and septicaemia. If a protein based vaccine could be produced that can protect against all strains of the pneumococcus, this would be of tremendous value and our discovery that NLRP3 is needed for protection will point us in the right direction in terms of how to develop such vaccines."

Citation: McNeela EA, Burke Á, Neill DR, Baxter C, Fernandes VE, et al. (2010) Pneumolysin Activates the NLRP3 Inflammasome and Promotes Proinflammatory Cytokines Independently of TLR4. PLoS Pathog 6(11): e1001191. doi:10.1371/journal.ppat.1001191

 

NOTE TO NEWSDESK:

PLEASE CITE TRINITY COLLEGE DUBLIN AND UNIVERSITY OF LEICESTER IN ANY REPORT

 

For more information contact:

At University of Leicester

Dr. Aras Kadioglu,

Reader in Respiratory Infection

Department of Infection Immunity & Inflammation

University of Leicester

Tel 0116-2522947

Email: [email protected]

 

At Trinity College Dublin

Dr Ed Lavelle

Lecturer in Immunology

School of Biochemistry and Immunology

Trinity College

Tel 01 8962488

Email: [email protected]

 

PRESS OFFICE CONTACTS:

Leicester: Ather Mirza, University of Leicester press office, 0116 252 3335; mobile 07711 927821  email [email protected]

Dublin:  Caoimhe Ní Lochlainn, Trinity College Dublin Press Officer,  tel:  +353-1-8962310\  mobile: +353-(0)87-99588014, email: [email protected]

 

Suggested Articles

Comet Therapeutics unveiled itself with $28.5 million in series A financing and biopharma veteran David De Graaf at the helm.

Frontage is Growing to Meet All Your Needs! Click Here to Learn About the Next Generation of Frontage.

Cara Care, a digital health startup focused on digestive diseases, raised $7 million to bring its mobile app to more patients in the U.S.